已收盘 03-04 16:00:00 美东时间
0.000
0.00%
文|《财经》记者 凌馨 研究员 丁宁 编辑 | 王小 替尔泊肽给了礼来寻找下一个增长曲线的底气 2026年8月5日,礼来发布二季度财报...
08-11 11:25
Equillium reported Q1 2026 financial results with $61.3M in cash and plans to initiate a Phase 1 study for EQ504 in mid-2026. Snehal Naik, Ph.D., was appointed Chief Development Officer, bringing extensive experience in immunology and clinical development. EQ504, a potent AhR modulator, showed promising preclinical data supporting its potential for treating ulcerative colitis and other inflammatory diseases. The company also highlighted progress ...
05-13 20:01
礼来正就收购私营生物技术公司Kelonia Therapeutics展开深入谈判,交易估值超过20亿美元。
04-20 07:40
Eli Lilly (LLY) is in advanced negotiations to acquire Kelonia Therapeutics in a transaction valued at more than $2 billion, The Wall Street Journal reported Sunday, citing people familiar with the di...
04-20 06:08
Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.
03-31 22:48
Ventyx Biosciences ( ($VTYX) ) has shared an update. On the closing date of a p...
03-04 22:49
今日重点评级关注:HC Wainwright & Co.:维持奥麦罗制药"买入"评级,目标价从20美元升至40美元;HC Wainwright & Co.:维持Cullinan Therapeutics"买入"评级,目标价从26美元升至27美元
01-09 20:22